{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:21:43Z","timestamp":1785799303834,"version":"3.56.0"},"reference-count":0,"publisher":"American Association for Cancer Research (AACR)","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In relapsed\/refractory large B-cell lymphoma (LBCL), chimeric antigen receptor (CAR)-natural killer (NK) cell therapies offer potential advantages over CAR-T-cell therapies, including off-the-shelf availability and scalable manufacturing. We performed a phase 2 study of single-dose TAK-007, a cryopreserved, cord blood-derived, off-the-shelf CD19 CAR-NK cell therapy, in 26 heavily pre-treated patients with relapsed\/refractory B-cell non-Hodgkin lymphoma (NHL). Adverse events were manageable, with limited grade 1\u20132 cytokine release syndrome (11.5%). Overall response rate with TAK-007 800 x106 CD19 CAR+ viable NK cells (n=14) was 60.9% (95% CI: 38.5\u201380.3). Median progression-free survival was 2.0 months (95% CI: 0.99\u20133.58) in LBCL (n=10) and 5.6 months (95% CI: 1.05\u20138.57) in indolent NHL (n=7) expansion cohorts. Deep molecular responses, including ctDNA-negative responses, were achieved. Not all TAK-007 products elicited clinical responses; single cell RNA-sequencing showed NK proliferating and NK-CD56dim cell enrichment in TAK-007 products eliciting\/not eliciting responses, respectively, which could inform product selection.<\/jats:p>","DOI":"10.1158\/2643-3230.bcd-25-0323-a","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T14:39:03Z","timestamp":1776436743000},"update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Phase 2, Open-Label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed\/Refractory B-cell Non-Hodgkin Lymphoma"],"prefix":"10.1158","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6557-4027","authenticated-orcid":false,"given":"Justin M.","family":"Darrah","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02pammg90","id-type":"ROR","asserted-by":"publisher"}],"name":"Cedars-Sinai Medical Center 1 Los Angeles, CA","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8737-4053","authenticated-orcid":false,"given":"Indumathy","family":"Varadarajan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0153tk833","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Virginia 2 Charlottesville, Virginia","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0537-4207","authenticated-orcid":false,"given":"Amitkumar","family":"Mehta","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01rm42p40","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Alabama at Birmingham Hospital 3 Birmingham, AL","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0024-9466","authenticated-orcid":false,"given":"Jennifer N.","family":"Saultz","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/009avj582","id-type":"ROR","asserted-by":"publisher"}],"name":"Oregon Health & Science University 4 Portland, Oregon","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2979-4882","authenticated-orcid":false,"given":"Matthew S.","family":"McKinney","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03njmea73","id-type":"ROR","asserted-by":"publisher"}],"name":"Duke Medical Center 5 Durham, NC","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2260-8212","authenticated-orcid":false,"given":"Monalisa","family":"Ghosh","sequence":"additional","affiliation":[{"name":"University of Michigan 6 Ann Arbor, Michigan","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0656-7385","authenticated-orcid":false,"given":"Usama","family":"Gergis","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00ysqcn41","id-type":"ROR","asserted-by":"publisher"}],"name":"Thomas Jefferson University 7 Philadelphia, Pennsylvania","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5817-0262","authenticated-orcid":false,"given":"Andrew","family":"Krueger","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03bygaq51","id-type":"ROR","asserted-by":"publisher"}],"name":"Takeda (United States) 8","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0311-4938","authenticated-orcid":false,"given":"Kevin J.","family":"Galinsky","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04hjbmv12","id-type":"ROR","asserted-by":"publisher"}],"name":"Takeda (Japan) 9 Cambridge, Massachusetts","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9357-1073","authenticated-orcid":false,"given":"Girish","family":"Bende","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc. (TDCA) 10 Cambridge, Massachusetts","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6308-9562","authenticated-orcid":false,"given":"Ajeetha","family":"Ramachandran","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc. (TDCA) 10 Cambridge, Massachusetts","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9129-0561","authenticated-orcid":false,"given":"Varsha","family":"Sundaresan","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc. (TDCA) 10 Cambridge, Massachusetts","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8633-4292","authenticated-orcid":false,"given":"Siddha","family":"Kasar","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc. (TDCA) 10 Cambridge, Massachusetts","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4180-9091","authenticated-orcid":false,"given":"Bradley","family":"Hupf","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc. (TDCA) 10 Cambridge, Massachusetts","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5097-9438","authenticated-orcid":false,"given":"Sharon","family":"Chen","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc. (TDCA) 10 Cambridge, Massachusetts","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7893-401X","authenticated-orcid":false,"given":"Leopold","family":"Sellner","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc. (TDCA) 10 Cambridge, Massachusetts","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0984-4376","authenticated-orcid":false,"given":"Reem","family":"Karmali","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/009543z50","id-type":"ROR","asserted-by":"publisher"}],"name":"Northwestern Memorial Hospital 11 Chicago, IL","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,4,17]]},"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-25-0323-A\/3774668\/bcd-25-0323.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-25-0323-A\/3774668\/bcd-25-0323.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T14:39:03Z","timestamp":1776436743000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/doi\/10.1158\/2643-3230.BCD-25-0323-A\/783930\/A-Phase-2-Open-Label-Multicenter-Study-of-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-25-0323-a","relation":{},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]}}}